New Federal Research Agenda Set for Drug-Resistant TB

The National Institute of Allergy and Infectious Diseases announced a new research agenda to fight drug-resistant tuberculosis in both of its forms -- multidrug-resistant (MDR) and extensively drug-resistant (XDR). Both "are occurring at an ominous and accelerating rate," according to the NIH agency's announcement. NIAID Director Dr. Anthony S. Fauci and members of the NIAID Tuberculosis Working Group created the agenda, which is available online in The Journal of Infectious Diseases.

"The TB diagnostic tools in use today are antiquated, slow, and insensitive; TB drug regimens are complex and lengthy; and the only vaccine available does not provide effective protection against adult pulmonary TB," said Fauci. "The challenge of TB control is further compounded by the rise of drug-resistant TB, and we anticipate that the NIAID Research Agenda for Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis will contribute substantively to the fight against this emerging threat."

The World Health Organization estimates 500,000 people worldwide have MDR-TB, while XDR-TB has been detected in 46 countries. Factors contributing to these increases include lack of routine testing to determine TB drug-sensitivity, incomplete treatment of people infected with TB-causing bacteria, an epidemic of TB in HIV-infected people, and limited TB research by pharmaceutical companies, the agency said.

The agenda identifies areas of biomedical research that are likely to contribute to a global public health response. The priorities include efforts to develop and test reliable technologies to rapidly diagnose TB and to identify drug resistance; define the most effective use of existing TB therapies and other antibiotics available to treat drug-resistant TB and develop new drugs, particularly to treat MDR-TB and XDR-TB; better understand the basic biology of TB-causing bacteria and their interaction with the human host that underlie the development of drug-resistant TB; understand the epidemiology of drug-resistant TB; investigate the various manifestations of TB in adults, children and those with co-infections, including HIV/AIDS; and conduct research to develop new vaccines and other preventive strategies.

Download Center

HTML - No Current Item Deck
  • Get the Ultimate Guide to OSHA Recordkeeping

    OSHA’s Form 300A posting deadline is February 1! Are you prepared? To help answer your key recordkeeping questions, IndustrySafe put together this guide with critical compliance information.

  • Steps to Conduct a JSA

    We've put together a comprehensive step-by-step guide to help you perform a job safety analysis (JSA), which includes a pre-built, JSA checklist and template, steps of a JSA, list of potential job hazards, and an overview of hazard control hierarchy.

  • Everything You Need to Know about Incident investigations

    Need some tips for conducting an incident investigation at work after there’s been an occupational injury or illness, or maybe even a near miss? This guide presents a comprehensive overview of methods of performing incident investigations to lead you through your next steps.

  • Free Safety Management Software Demo

    IndustrySafe Safety Management Software helps organizations to improve safety by providing a comprehensive toolset of software modules to help businesses identify trouble spots; reduce claims, lost days, OSHA fines; and more.

  • Industry Safe
Bulwark CP

OH&S Digital Edition

  • OHS Magazine Digital Edition - October 2020

    October 2020

    Featuring:

    • FACILITY SECURITY
      EHS Compliance: Make it Personal
    • FOOT PROTECTION
      Choosing the Right Safety Shoe for Your Industry
    • HAND PROTECTION
      A Requirements Checklists for Work Safety Gloves
    • COVID-19 MANAGEMENT
      Contemporary Issues in HSE Management
    View This Issue